Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Synta Pharmaceuticals Corp.)"
Count: 38
Selected: 0
NCT IDTitle
NCT01798485A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
NCT01677455An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
NCT01562015A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT01348126Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
NCT01280786Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01183364A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors
NCT01039519A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)
NCT01031225A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
NCT00964873A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia
NCT00858572STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
NCT00827203A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors
NCT00808418A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer
NCT00688116Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
NCT00687934Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
NCT00642629A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes
NCT00522834Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma
NCT00276913A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors
NCT00234741Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease
NCT00138840Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease
NCT00088114STA-4783 and Paclitaxel for Treatment of Solid Tumors
NCT00088101STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors
NCT00088088STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
NCT00088062STA-5326 in Crohn's Disease Patients
NCT00087997A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas
NCT00084214STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma
NCT02334319Ganetespib Window of Opportunity Study in Head and Neck Cancers
NCT02261805A Phase I/II Study of Ganetespib in Combination With Doxorubicin
NCT01554969Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer
NCT01551693STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
NCT01273896Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
NCT01111838Clinical and Translational Study of STA-9090
NCT02008877SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
NCT01485835A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT02060253Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
NCT01665937STA-9090 in Patients With Advanced Hepatocellular Cancer
NCT01173523Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
NCT01167114STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
NCT01200238STA-9090(Ganetespib) in Metastatic Ocular Melanoma